Progress in the Research and Application of Tumor Organoids in Drug Screening and Personalized Drug Treatment

doi:10.13523/j.cb.2201029

China Biotechnology

2022, Vol. 42

Issue (6): 47-53 DOI: 10.13523/j.cb.2201029

Progress in the Research and Application of Tumor Organoids in Drug Screening and Personalized Drug Treatment

YANG Huan-lian¹,QIU Fei(

),WANG Guo-quan^1,^2,^3,^**,DIAO Yong

1. School of Medicine, Huaqiao University, Quanzhou 362021, China
2. School of Biomedical Sciences, Huaqiao University, Quanzhou 362021, China
3. Engineering Research Center for Molecular Medicine of Ministry of Education, Quanzhou 362021, China

Download:

HTML

PDF(1082KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Malignant tumor is one of the major diseases that threaten human life, and drug therapy is a common method. Currently, precision treatment has become a trend of tumor therapy. To achieve effective and precise drug therapy for malignant tumors, the drug screening models are very important points. Tumor organoids are three-dimensional cell models which have emerged in recent years. They have the advantages of retaining the characteristics and heterogeneity of parental tumors during long-term culture, with high success rate of culture and short culture cycle, and they can be used for high-throughput drug screening. They have been used for drug screening, predicting patients’ response of drug therapy, and providing guidance for personalized drug treatment. The progress of tumor organoids in drug screening and personalized drug treatment, and possible challenges were introduced.

Key words： Tumor organoids Drug screening Personalized drug treatment Precision treatment Tumor

Received: 21 January 2022 Published: 07 July 2022

ZTFLH:

R965

Corresponding Authors: Fei QIU,Guo-quan WANG,Yong DIAO E-mail: qiufei@hqu.edu.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Huan-lian YANG
	Fei QIU
	Guo-quan WANG
	Yong DIAO

Cite this article:

YANG Huan-lian,QIU Fei,WANG Guo-quan,DIAO Yong. Progress in the Research and Application of Tumor Organoids in Drug Screening and Personalized Drug Treatment. China Biotechnology, 2022, 42(6): 47-53.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2201029 OR https://manu60.magtech.com.cn/biotech/Y2022/V42/I6/47

Fig.1 Application of tumor organoids


[1]	Moffat J G, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nature Reviews Drug Discovery, 2014, 13(8): 588-602. doi: 10.1038/nrd4366 pmid: 25033736

[2]	高彤, 丁冠守, 苏萍萍, 等. 药物筛选模型的研究进展. 海峡药学, 2021, 33(7): 1-5.

[2]	Gao T, Ding G S, Su P P, et al. Advances in drug screening models. Strait Pharmaceutical Journal, 2021, 33(7): 1-5.

[3]	Pauli C, Hopkins B D, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discovery, 2017, 7(5): 462-477. doi: 10.1158/2159-8290.CD-16-1154

[4]	Nguyen L V, Caldas C. Functional genomics approaches to improve pre-clinical drug screening and biomarker discovery. EMBO Molecular Medicine, 2021, 13(9): e13189.

[5]	Tsimberidou A M, Fountzilas E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treatment Reviews, 2020, 86: 102019. doi: 10.1016/j.ctrv.2020.102019

[6]	Chen Y J, Juan L R, Lv X, et al. Bioinformatics research on drug sensitivity prediction. Frontiers in Pharmacology, 2021, 12: 799712. doi: 10.3389/fphar.2021.799712

[7]	Huo K G, D’Arcangelo E, Tsao M S. Patient-derived cell line, xenograft and organoid models in lung cancer therapy. Translational Lung Cancer Research, 2020, 9(5): 2214-2232. doi: 10.21037/tlcr-20-154

[8]	Klinghammer K, Walther W, Hoffmann J. Choosing wisely-preclinical test models in the era of precision medicine. Cancer Treatment Reviews, 2017, 55: 36-45. doi: S0305-7372(17)30028-2 pmid: 28314175

[9]	Pyo D H, Hong H K, Lee W Y, et al. Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line. Cancer Biology & Therapy, 2020, 21(6): 495-502.

[10]	Zhuo J Y, Su R Y, Tan W, et al. The ongoing trends of patient-derived xenograft models in oncology. Cancer Communications, 2020, 40(11): 559-563. doi: 10.1002/cac2.12096

[11]	Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer, 2018, 18(7): 407-418. doi: 10.1038/s41568-018-0007-6

[12]	Chen H D, Zhuo Q F, Ye Z, et al. Organoid model: a new hope for pancreatic cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021, 1875(1): 188466. doi: 10.1016/j.bbcan.2020.188466

[13]	Chan A S, Yan H H N, Leung S Y. Breakthrough moments: organoid models of cancer. Cell Stem Cell, 2019, 24(6): 839-840. doi: 10.1016/j.stem.2019.05.006

[14]	Kelly P N. Cancer organoids to model therapy response. Science, 2018, 359(6378): 880-881. doi: 10.1126/science.2018.359.6378.twis

[15]	Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell, 2014, 159(1): 176-187. doi: 10.1016/j.cell.2014.08.016

[16]	Broutier L, Mastrogiovanni G, Verstegen M M, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nature Medicine, 2017, 23(12): 1424-1435. doi: 10.1038/nm.4438 pmid: 29131160

[17]	冯紫伊, 梁珊珊, 于炜婷, 等. 患者来源肿瘤类器官的培养与研究及应用. 中国组织工程研究, 2021, 25(25): 4082-4088.

[17]	Feng Z Y, Liang S S, Yu W T, et al. Culture, research and application of patient-derived tumor organoids. Chinese Journal of Tissue Engineering Research, 2021, 25(25): 4082-4088.

[18]	高坚钧, 秦伟, 王浩, 等. 类器官技术在肿瘤研究中的应用与展望. 中国组织工程研究, 2019, 23(7): 1136-1141.

[18]	Gao J J, Qin W, Wang H, et al. Application and prospect of organoid technique in cancer research. Chinese Journal of Tissue Engineering Research, 2019, 23(7): 1136-1141.

[19]	李甜瑞, 赵瑞波, 张权, 等. 类器官及其应用的研究进展. 生物化学与生物物理进展, 2019, 46(8): 737-750.

[19]	Li T R, Zhao R B, Zhang Q, et al. Progress in the research of organoids and applications. Progress in Biochemistry and Biophysics, 2019, 46(8): 737-750.

[20]	张健. 基于转录组数据挖掘的肿瘤异质性与肿瘤免疫微环境研究. 北京: 军事科学院, 2019.

[20]	Zhang J. Mining large-scale tumor transcriptome profiles to inform cancer heterogeneity and immune microenvironment. Beijing: Academy of Military Sciences, 2019.

[21]	Bonin S, Stanta G. Pre-analytics and tumor heterogeneity. New Biotechnology, 2020, 55: 30-35. doi: 10.1016/j.nbt.2019.09.007

[22]	Kim J. Cellular reprogramming to model and study epigenetic alterations in cancer. Stem Cell Research, 2020, 49: 102062. doi: 10.1016/j.scr.2020.102062

[23]	Tiriac H, Plenker D, Baker L A, et al. Organoid models for translational pancreatic cancer research. Current Opinion in Genetics & Development, 2019, 54: 7-11.

[24]	Buzzelli J N, Ouaret D, Brown G, et al. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Research, 2018, 27: 109-120. doi: S1873-5061(18)30022-9 pmid: 29414601

[25]	van de Wetering M, Francies H E, Francis J M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015, 161(4): 933-945. doi: 10.1016/j.cell.2015.03.053 pmid: 25957691

[26]	Seidlitz T, Koo B K, Stange D E. Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine. Cell Death & Differentiation, 2021, 28(1): 68-83.

[27]	Frappart P O, Walter K, Gout J, et al. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. United European Gastroenterology Journal, 2020, 8(5): 594-606. doi: 10.1177/2050640620905183

[28]	Lee S H, Hu W H, Matulay J T, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell, 2018, 173(2): 515-528, e17. doi: 10.1016/j.cell.2018.03.017

[29]	Nanki Y, Chiyoda T, Hirasawa A, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Scientific Reports, 2020, 10(1): 12581. doi: 10.1038/s41598-020-69488-9

[30]	Saifuddin S R, Devlies W, Santaolalla A, et al. King’s health partners’ prostate cancer biobank (KHP PCaBB). BMC Cancer, 2017, 17(1): 784. doi: 10.1186/s12885-017-3773-8 pmid: 29166865

[31]	Kim M, Mun H, Sung C O, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications, 2019, 10(1): 3991. doi: 10.1038/s41467-019-11867-6

[32]	Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell, 2018, 172(1-2): 373-386, e10. doi: 10.1016/j.cell.2017.11.010

[33]	Kenny H A, Lal-Nag M, White E A, et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nature Communications, 2015, 6: 6220. doi: 10.1038/ncomms7220

[34]	Brancato V, Oliveira J M, Correlo V M, et al. Could 3D models of cancer enhance drug screening. Biomaterials, 2020, 232: 119744. doi: 10.1016/j.biomaterials.2019.119744

[35]	颜畅, 胡艺冰, 赵晖, 等. CEA-TCB双特异性抗体cibisatamab增强T细胞对胃癌类器官的免疫杀伤作用. 华中科技大学学报(医学版), 2020, 49(5): 511-516.

[35]	Yan C, Hu Y B, Zhao H, et al. Effect of CEA-CD 3 bispecific antibody cibisatamab in enhancing T cells immunocompetence in gastric cancer organoids. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2020, 49(5): 511-516.

[36]	Zumwalde N A, Haag J D, Sharma D, et al. Analysis of immune cells from human mammary ductal epithelial organoids reveals Vδ2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate. Cancer Prevention Research (Philadelphia, Pa), 2016, 9(4): 305-316.

[37]	Cattaneo C M, Dijkstra K K, Fanchi L F, et al. Tumor organoid-T-cell coculture systems. Nature Protocols, 2020, 15(1): 15-39. doi: 10.1038/s41596-019-0232-9 pmid: 31853056

[38]	Litman T. Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases. APMIS, 2019, 127(5): 386-424. doi: 10.1111/apm.12934

[39]	Goetz L H, Schork N J. Personalized medicine: motivation, challenges, and progress. Fertility and Sterility, 2018, 109(6): 952-963. doi: 10.1016/j.fertnstert.2018.05.006

[40]	Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359(6378): 920-926. doi: 10.1126/science.aao2774 pmid: 29472484

[41]	Yan H H N, Siu H C, Law S, et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell, 2018, 23(6): 882-897, e11. doi: 10.1016/j.stem.2018.09.016

[42]	Broekgaarden M, Rizvi I, Bulin A L, et al. Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. Oncotarget, 2018, 9(16): 13009-13022. doi: 10.18632/oncotarget.24425 pmid: 29560127

[43]	Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proceedings of the National Academy of Sciences, 2019, 116(52): 26580-26590.

[44]	Verissimo C S, Overmeer R M, Ponsioen B, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. eLife, 2016, 5: e18489. doi: 10.7554/eLife.18489

[45]	路小欢, 徐鲁明, 王星月, 等. 结直肠癌类器官的构建与应用进展. 中华医学杂志, 2019, 99(36): 2878-2880.

[45]	Lu X H, Xu L M, Wang X Y, et al. Progress in the construction of colorectal cancer organoids and applications. National Medical Journal of China, 2019, 99(36): 2878-2880.

[46]	Ooft S N, Weeber F, Schipper L, et al. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open, 2021, 6(3): 100103. doi: 10.1016/j.esmoop.2021.100103

[47]	Liu C, Qin T Y, Huang Y H, et al. Drug screening model meets cancer organoid technology. Translational Oncology, 2020, 13(11): 100840. doi: 10.1016/j.tranon.2020.100840

[48]	Yanagisawa K, Konno M, Liu H, et al. A four-dimensional organoid system to visualize cancer cell vascular invasion. Biology, 2020, 9(11): 361. doi: 10.3390/biology9110361

[49]	Dijkstra K K, Cattaneo C M, Weeber F, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell, 2018, 174(6): 1586-1598, e12. doi: S0092-8674(18)30903-6 pmid: 30100188

[50]	Li Y Q, Tang P Y, Cai S J, et al. Organoid based personalized medicine: from bench to bedside. Cell Regeneration (London, England), 2020, 9(1): 21.

[51]	罗升昌, 王颖, 王士斌, 等. 基于微流控技术构建3D肿瘤模型用于药物筛选. 科学通报, 2021, 66(34): 4395-4410.

[51]	Luo S C, Wang Y, Wang S B, et al. Construction of 3D-tumor model for drug screening: application of microfluidics. Chinese Science Bulletin, 2021, 66(34): 4395-4410.

[52]	Kim E, Choi S, Kang B, et al. Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature, 2020, 588(7839): 664-669. doi: 10.1038/s41586-020-3034-x

[53]	Ji D B, Wu A W. Organoid in colorectal cancer: progress and challenges. Chinese Medical Journal, 2020, 133(16): 1971-1977. doi: 10.1097/CM9.0000000000000882

[54]	Hu Y, Sui X, Song F, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nature Communications, 2021, 12: 2581. doi: 10.1038/s41467-021-22676-1

[1]	Zi-rong YANG,Xuan YANG,Ting-ting NI,Cong PAN,Shi-sheng TAN,Zi WANG. Carrimycin Affects Melanoma Proliferation by Regulating Macrophage Polarization[J]. China Biotechnology, 2022, 42(7): 12-23.

[2]	WANG Lu,CHEN Meng-li,HE Fang,XIANG Jian,YIN Bin-cheng,YE Bang-ce. Clearance of Tumor Exosomes by Engineered Exosomes-assisted Phagocytosis of Macrophages[J]. China Biotechnology, 2022, 42(6): 1-11.

[3]	MAO Lu-jia,SHI En-yu,WANG Han-ping,SHAN Tian-he,WANG Yin-song,WANG Yue. Research Progress of Bacterial Outer Membrane Vesicles in Anti-tumor Therapy[J]. China Biotechnology, 2022, 42(5): 100-105.

[4]	FENG Xiao-ying,MENG Qian,CHEN Wei,YU Lei,HUANG Wei-ren. Application Progress of Organoids-on-a-chip in Medical Research[J]. China Biotechnology, 2022, 42(1/2): 112-118.

[5]	ZHANG Hui,CHEN Hua-ning,KUDELAIDI Kuerban,WANG Song-na,LIU Jia-yang,ZHAO Zhen,YE Li. The Role of Wnt/β-catenin Signaling Pathway in Carcinogenesis and Immunotherapy[J]. China Biotechnology, 2022, 42(1/2): 104-111.

[6]	ZHAO Meng-ze,LI Feng-zhi,WANG Peng-yin,LI Jian,XU Han-mei. Research Progress of Dual-target Blocking Therapy of PD-L1 and VEGF[J]. China Biotechnology, 2021, 41(9): 71-77.

[7]	LV Hui-zhong,ZHAO Chen-chen,ZHU Lian,XU Na. Progress of Using Exosome for Drug Targeted Delivery in Tumor Therapy[J]. China Biotechnology, 2021, 41(5): 79-86.

[8]	YUAN Bo,WANG Jie-wen,KANG Guang-bo,HUANG He. Research Progress and Application of Bispecific Nanobody[J]. China Biotechnology, 2021, 41(2/3): 78-88.

[9]	DENG Rui,ZENG Jia-li,LU Xue-mei. *Screening and Structure-activity Relationship Analysis of Anti-tumor Derived Peptides Based on Musca domestica* cecropin**[J]. China Biotechnology, 2021, 41(11): 14-22.

[10]	LIN Shi-xin,LIU Dong-chen,LEI Yun,XIONG Sheng,XIE Qiu-ling. Screening, Expression and Specificity Detection of Anti-TNF-α Nanobody[J]. China Biotechnology, 2020, 40(7): 15-21.

[11]	YANG Wei,SONG Fang-xiang,WANG Shuai,ZHANG Li,WANG Hong-xia,LI Yan. Preparation and Application of Janus Nanoparticles in Drug Delivery System[J]. China Biotechnology, 2020, 40(7): 70-81.

[12]	ZHANG Bao-hui,XIONG Hua-long,ZHANG Tian-ying,YUAN Quan. Research Progress on Vesicular Stomatitis Virus-based Oncolytic Virotherapy[J]. China Biotechnology, 2020, 40(6): 53-62.

[13]	TONG Mei,CHENG Yong-qing,LIU Jin-yi,XU Chen. Construction of a Strain for Promoting Production of Small Molecule Antibodies in Periplasmic Space of Escherichia coli[J]. China Biotechnology, 2020, 40(5): 48-56.

[14]	DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.

[15]	QIAN Ying,QIAN Chen,BAI Xiao-qing,WANG Jing-jing. Application of Adjuvant in Cancer Immunotherapy[J]. China Biotechnology, 2020, 40(3): 96-103.

Viewed

Full text

Abstract

Cited

Shared

Discussed